Thursday, July 9, 2026
🇺🇸 FDA

Drug profile · INN

acamprosate calcium

ACAMPROSATE CALCIUM

acamprosate calcium (ACAMPROSATE CALCIUM) is a gaba-a receptor; anion channel positive modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 2
News articles 0
Drug details — acamprosate calcium
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
2
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

acamprosate calcium (ACAMPROSATE CALCIUM) is a gaba-a receptor; anion channel positive modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN acamprosate calcium
Brand ACAMPROSATE CALCIUM
Mechanism GABA-A receptor; anion channel positive modulator
Target GABA-A receptor; anion channel
Route ORAL
Formulation TABLET, DELAYED RELEASE
Originator Teva Pharma GmbH

Mechanism of action

GABA-A receptor; anion channel positive modulator

Primary target: GABA-A receptor; anion channel

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Orforglipron Phase 3 · Eli Lilly and · OSA
  2. PRA Phase 1 · CNS Pharmaceuticals · Pharmacokinetics

Related & competitor drugs

Browse all drugs
  1. alprazolam GABA-A receptor; anion channel positive allosteric modulator
  2. butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
  3. chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
  4. clobazam GABA-A receptor; anion channel positive allosteric modulator
  5. clonazepam GABA-A receptor; anion channel positive allosteric modulator
  6. clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator

Related patents

Browse patents Teva Pharma GmbH patent hub

  1. US 12139528

    Treating refractory migraine

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12091388

    Solid state forms of Reproxalap

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11826322

    Pre-filled syringe

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11578338

    Hemipteran active insecticidal protein

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11319356

    Interferon alpha 2B variants

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11297838

    Pesticidal compositions and methods

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11028161

    Treating refractory migraine

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11028160

    Treating refractory migraine

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10835503

    Pre-filled syringe

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10544199

    Interferon alpha 2B variants

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10392434

    Treating refractory migraine

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10342867

    Adjuvants

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10323085

    Methods of treating fibromyalgia

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9346746

    R(+)-N-formyl-propargyl-aminoindan

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9339469

    R(+)-N-methyl-propargyl-aminoindan

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9284276

    N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof

    Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9220692

    Methods of reducing symptoms in subjects using single dosage forms with tapering release rates

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9102620

    Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8980304

    Barrel-shaped vaginal ring

    Expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8962847

    Multicomponent crystals made of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and an arylpropionic acid

    Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is acamprosate calcium?

acamprosate calcium (ACAMPROSATE CALCIUM) is a gaba-a receptor; anion channel positive modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for acamprosate calcium?

ACAMPROSATE CALCIUM is a marketed brand name for acamprosate calcium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of acamprosate calcium?

acamprosate calcium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.